ArticleHeliyon2025
Effect of adipose mesenchymal stem cell-derived exosomes on allergic rhinitis in mice.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- UC-MSCs-derived exosomal circFOXP1 alleviates allergic rhinitis through EZH2/EGR1/Blimp-1 axis.Respiratory research · 2026Article
- Advances in Nanotechnology-Based Immunomodulatory Strategies for the Treatment of Allergic Rhinitis.International journal of nanomedicine · 2026Review
- Multiple tail vein injections of adipose-derived mesenchymal stem cells ameliorate allergic rhinitis in mice: superior efficacy of prolonged regimens.Frontiers in immunology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: At present, the treatment for allergic rhinitis (AR) is only limited to symptom relief, and AR is not able be cured. It is important to find new therapeutic regimens for AR. Objective: To explore the effect of adipose mesenchymal stem cell-derived exosomes (AMSC-exos) on AR in mice. Methods: Primary human AMSCs were cultured up to fourth or fifth passage AMSCs which were used to extract AMSC-exos by ultracentrifugation. The AMSC-exos were identified in size, morphology and surface marker proteins. AR mouse models were made, and then effects of the AMSC-exos on AR mouse models were observed by injection of AMSC-exos into their tail veins. A total of 21 mice were divided into normal mice with injection of phosphate buffered saline (PBS) group (Normal + PBS group, 7 mice), AR mice with injection of AMSC-exos group (AR + AMSC-exos group, 7 mice) and AR mice with injection of PBS (AR + PBS group, 7 mice). After injection of AMSC-exos and PBS, symptoms were observed in mice and inflammatory factors including IL-4, IL-5, IFN- γ and Ig-E were determined. Mice were sacrificed, nasal mucosa was collected for HE staining and qRT-PCR. Results: After injection of AMSC-exos, compared with the AR + PBS group, symptoms were significantly improved, inflammatory factor levels were significantly decreased, disturbed and thickened mucosal layer was relieved, and the numbers of goblet cells and eosinophils were reduced in the AR + AMSC-exos group. Conclusion: AMSC-exos can improve symptoms and inflammatory level in the AR mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.